Tagworks Pharmaceuticals BV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tagworks Pharmaceuticals BV - overview
Established
2011
Location
Arnhem, -, Netherlands
Primary Industry
Pharmaceuticals
About
Founded in 2011 and based in the Netherlands, Tagworks Pharmaceuticals BV operates as a developer of antibody-drug-conjugates and therapeutic technology intended to boost the effectiveness of cancer treatments. In June 2023, Tagworks Pharmaceuticals BV raised USD 65 million in series A funding co-led by Gilde Healthcare Partners, and Ysios Capital Partners with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures. As of 2023, the company is led by its CEO, Marc Robillard. Tagworks Pharma provides comprehensive packaging solutions that ensure product safety, regulatory compliance, and efficient supply chain management.
The company’s product pipeline includes TGW101, an antibody-drug conjugate (ADC) targeting TAG72, a clinically-validated, pan-carcinoma target that so far has remained out of reach of current ADC therapies. The company plans to use the June 2023 funding to broaden the pipeline and progress click-cleavable ADC targeting TAG72, into clinical trials.
Current Investors
New Enterprise Associates, Novartis Venture Fund, Gilde Healthcare
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.tagworkspharma.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.